Review: Inefficacy of therapeutic cancer vaccines and proposed improvements. casus of prostate cancer

Anticancer Research

Volumn 34, Issue 6, 2014, Pages 2689-2700

  Jacobs, John J L ^a   Snackey, Chantal ^a,b   Geldof, Albert A ^a   Characiejus, Dainius ^c   Van Moorselaar, R Jeroen A ^a   Den Otter, Willem ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Department of Orthopaedic Surgery   (Netherlands)

^c VILNIUS UNIVERSITY   (Lithuania)

Author keywords

Cancer; Clinical; Immunotherapy; Review; Therapeutic vaccination

Indexed keywords

CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DNA VACCINE; DOCETAXEL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MITOXANTRONE; PEPTIDE VACCINE; PROSTATE SPECIFIC ANTIGEN; SIPULEUCEL T; TELOMERASE REVERSE TRANSCRIPTASE;

ADVANCED CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; DRUG EFFICACY; DRUG TREATMENT FAILURE; HUMAN; IMMUNOLOGICAL TOLERANCE; PROSTATE CANCER; REVIEW; T LYMPHOCYTE; CLINICAL; IMMUNOTHERAPY; MALE; NEOPLASM; PROSTATE TUMOR; STANDARD; THERAPEUTIC VACCINATION; VACCINATION;

CANCER; CLINICAL; IMMUNOTHERAPY; REVIEW; THERAPEUTIC VACCINATION;

CANCER VACCINES; HUMANS; IMMUNOTHERAPY; MALE; PROSTATIC NEOPLASMS; VACCINATION;

EID: 84906324292     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Review

References (145)

1. Coley WB: The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of 10 original cases. 1893. Clin Orthopaed Rel Res 262: 3-11, 1991.
2. Green HN: An immunological concept of cancer: a preliminary report. Br Med J 2: 1374-1380, 1954.
3. Rosenberg SA, Yang JC and Restifo NP: Reply to "Cancer vaccines: pessimism in check". Nat Med 10: 1279-1280, 2004.
4. Van der Sande MA, Waight PA, Mendy M, Zaman S, Kaye S, Sam O, Kahn A, Jeffries D, Akum AA, Hall AJ, Bah E, McConkey SJ, Hainaut P and Whittle HC: Long-term protection against HBV chronic carriage of Gambian adolescents vaccinated in infancy and immune response in HBV booster trial in adolescence. PLoS One 15: e753, 2007.
5. Gissmann L and Nieto K: The therapeutic vaccine: is it feasible? Arch Med Res 40: 493-498, 2009.
6. Stanley M: Prophylactic human papillomavirus vaccines: Will they do their job? J Internal Med 267: 251-259, 2010.
7. Pardoll D and Drake C: Immunotherapy earns its spot in the ranks of cancer therapy. J Exp Med 209: 201-209, 2012.
8. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF, T A, A A, Arseneau J, Barth N, Bernstein G, Bracken B, Burch P, Caggiano V, Chin J, Chodak G, Chu F, Corman J, Curti B, Dawson N, Deeken JF, Dubernet T, Fishman M, Flanigan R, Gailani F, Garbo L, Gardner T, Gelmann E, George D, Godfrey T, Gomella L, Guerra M, Hall S, Hanson J, Israeli R, Jancis E, Jewett MA, Kassabian V, Katz J, Klotz L, Koeneman K, Koh H, Kratzke R, Lance R, Lech J, Leichman L, Lemon R, Liang J, Libertino J, Lilly M, Malik I, Martin SE, McCaffrey J, McLeod D, McNeel D, Miles B, Murdock M, Nabhan C, Nemunaitis J, Notter D, Pantuck A, Perrotte P, Pessis D, Petrylak D, Polikoff J, Pommerville P, Ramanathan S and Rarick M: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New Engl J Med 363: 411-422, 2010.
9. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, Dahut WL, Arlen PM, Gulley JL and Godfrey WR: Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol 28: 1099-1105, 2010.
10. Jacobs JJL, Characiejus D, Scheper RJ, Stewart RJE, Tan JFV, Tomova R, Krastev Z and Den Otter W: The Amiens Strategy: Small Phase III Trials for Clinically Relevant Progress in the War Against Cancer. J Clin Oncol 27: 3062-3063, 2009.
11. Stewart DJ and Kurzrock R: Comments and Controversies. Cancer: The road to Amiens. J Clin Oncol 27: 328-333, 2009.
12. Huber ML, Haynes L, Parker C, and Iversen P: Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer. J Natl Cancer Inst 104: 273-279, 2012.
13. Siegel R, Naishadham D, and Jemal A: Cancer Statistics, 2013. CA: Cancer J Clin 63: 11-30, 2013.
14. Berrino F, De Angelis R, Sant M, Rosso S, Lasota MB, Coebergh JW, Santaquilani M, and the EUROCARE Working group: Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncol 8: 773-783, 2007.
15. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, and TAX 327 Investigators: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New Engl J Med 351: 205-206, 2004.
16. Calabrò F and Sternberg CN: Current indications for chemotherapy in prostate cancer patients. Eur Urol 51: 17-26, 2007.
17. Mike S, Harrison C, Coles B, Staffurth J, Wilt TJ and Mason MD: Chemotherapy for hormone-refractory prostate cancer. Cochrane Database Syst Rev 18: CD005247, 2006.
18. Sternberg CN: Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer. Ann Oncol 19: vii91-95, 2008.
19. Novellino L, Castelli C and Parmiani G: A listing of human tumor antigens recognized by T-cells: March 2004 update. Cancer Immunol Immunother 54: 187-207, 2005.
20. Weinschenk T, Gouttefangeas C, Schirle M, Obermayr F, Walter S, Schoor O, Kurek R, Loeser W, Bichler KH, Wernet D, Stevanovic S and Rammensee HG: Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res 62: 5818-5827, 2002.
21. Li Y, Cozzi PJ and Russel PJ: Promising tumor-associated antigens for future prostate cancer therapy. Med Res Rev 30: 67-101, 2010.
22. Solin T, Kontturi M, Pohlmann R and Vihko P: Gene expression and prostate specificity of human prostatic acid phosphatase (PAP): evaluation by RNA blot analyses. Biochim Bioph Acta 1048: 72-77, 1990.
23. Couzin-Frankel J: Cancer Immunotherapy. Science 342: 1432-1433 2013.
24. Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV and Valone FH: Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 18: 3894-3903, 2000.
25. Burch PA, Croghan GA, Gastineau DA, Jones LA, Kaur JS, Kylstra JW, Richardson RL, Valone FH and Vuk-Pavlovic S: Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a phase II trial. Prost 60: 197-204, 2004.
26. Rini BI, Weinberg V, Fong L, Conry S, Hershberg RM and Small EJ: Combination immunotherapy with prostatic acid phosphatase-pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer 107: 67-74, 2006.
27. Burch PA, Breen JK, Buckner JC, Gastineau DA, Kaur JA, Laus RL, Padley DJ, Peshwa MV, Pitot HC, Richardson RL, Smits BJ, Sopapan P, Strang G, Valone FH and Vuk-Pavlovic S: Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 6: 2175-2182, 2000.
28. Small EJ, Sacks N, Nemunaitis J, Urba WJ, Dula E, Centeno AS, Nelson WG, Ando D, Howard C, Borellini F, Nguyen M, Hege K and Simons JW: Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res 13: 3883-3891, 2007.
29. Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, Humphrey R, Blumenstein B, Old L and Wolchok J: Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 102: 1388-1397, 2010.
30. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
31. Smith MR and Kantoff PW: Changes in PSA kinetics after DNA vaccine therapy-Not so fast! J Clin Oncol 28: 58, 2010.
32. Sindhwani P and Wilson CM: Prostatitis and serum prostate-specific antigen. Curr Urol Rep 6: 307-312, 2005.
33. Kobayashi M, Nukui A, and Morita T: Serum PSA and percent free PSA value changes after antibiotic treatment. A diagnostic method in prostate cancer suspects with asymptomatic prostatitis. Urol Int 80: 186-192, 2008.
34. Loeb S, Gashti SN and Catalona WJ: Exclusion of inflammation in the differential diagnosis of an elevated prostate-specific antigen (PSA). Urol Oncol 27: 64-6, 2009.
35. Beltrami P, Ruggera L, Cazzoletti L, Schiavone D and Zattoni F: Are prostate biopsies mandatory in patients with prostate-specific antigen increase during intravesical immuno-or chemotherapy for superficial bladder cancer? Prost 68: 1241-1247, 2008.
36. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M, and Prostate Cancer Clinical Trials Working Group: Design and endpoints of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26: 1148-1159, 2008.
37. Collette L, Burzykowski T, Carroll KJ, Newling D, Morris T, Schröder FH, Cancer EOfRaTo, Centrum LU, and Pharmaceuticals. A: Is prostate-specific antigen a valid surrogate endpoint for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals. J Clin Oncol 23: 6139-6148, 2005.
38. Collette L, Burzykowski T and Schröder FH: Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials. Eur J Cancer 42: 1344-1350, 2006.
39. Collette L: Prostate-specific antigen (PSA) as a surrogate endpoint for survival in prostate cancer clinical trials. Eur Urol 53: 6-9, 2008.
40. Jacobs JJL, Characiejus D, Tomova R, Baran J, Bubenik J, Zembala M, Krastev Z, Scheper RJ, Pawelec G and Den Otter W: Local, rather than systemic immunotherapy has therapeutic efficacy against metastasized cancer. Trends Cancer Res 7: 1-14, 2011.
41. Den Otter W, Jacobs JJL, Battermann JJ, Hordijk GJ, Krastev Z, Moiseeva EV, Stewart RJE, Ziekman PGPM and Koten JW: Local therapy of cancer with free IL-2. Cancer Immunol Immunother 57: 931-950, 2008.
42. + T-cells infiltrating prostatic tumors are induced to become suppressor cells. J Immunol 183: 4848-4852, 2009.
43. Ha T-Y: Regulatory T cell in cancer. Immune Network 9: 209-235, 2009.
44. + lymphocytes is thymus and proliferation independent. Cancer Res 66: 4488-4495, 2006.
45. + regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res 14: 1032-1040, 2008.
46. high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 177: 7398-7405, 2006.
47. Sfanos KS, Bruno TC, Maris CH, Xu L, Thoburn CJ, DeMarzo AM, Meeker AK, Isaacs WB and Drake CG: Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res 14: 3254-3261, 2008.
48. + lymphocytes modulate prostate cancer progression in mice. Int J Cancer 125: 868-878, 2009.
49. +. Prost 69: 1694-1703, 2009.
50. + regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res 13: 6947-6958, 2007.
51. + T-Cells. J Exp Med 198: 569-580, 2003.
52. + regulatory T cells. Cancer Res 68: 292-300, 2008.
53. Zhou G, Drake CG and Levitsky HI: Amplification of tumor-specific regulatory T-cells following therapeutic cancer vaccines. Blood 107: 629-636, 2006.
54. Lees JR and Farber DL: Generation, persistence and plasticity of CD4 T-cell memories. Immunology 130: 463-470, 2010
55. Ahmadzadeh M and Farber DL: Functional plasticity of an antigen-specific memory CD4 T cell population. Proc Nat Acad Sci USA 99: 11802-11807, 2002
56. Oleinika K, Nibbs RJ, Graham GJ and Fraser AR: Suppression, subversion and escape: the role of regulatory T-cells in cancer progression. Clin Exp Immunol 171: 36-45, 2013
57. + T cell-based therapeutic vaccination. Arch Immunol Ther Exp (Warsz) 55: 205-217, 2007.
58. Ricupito A, Grioni M, Calcinotto A, Michelini RH, Longhi R, Mondino A and Bellone M: Booster Vaccinations against Cancer Are Critical in Prophylactic but Detrimental in Therapeutic Settings. Cancer Res 73: 3545-3554, 2013.
59. da Silva Martins M and Piccirillo CA: Functional stability of FoxP3+ regulatory T cells. Trends Mol Med 18: 454-462, 2012.
60. Gerritsen WR, Kwon ED, and Fizazi K: Ipilimumab does not significantly improve survival in patients with advanced CRPC but may have most benefit on patients with lower disease burden. Oncol Ex 12: 30-31, 2013.
61. Gates JD, Benavides LC, Carmichael MG, Holmes JP, Hueman MT, Mittendorf EA, McLeod DG, Ponniah S and Peoples GE: Long-term follow-up assessment of a HER-2/neu peptide (E75) vaccine for the prevention of recurrence in high-risk prostate cancer patients. J Clin Oncol 26: (15S) 3067, 2008.
62. Kantele A, Kantele JM, Savilahti E, Westerholm M, Arvilommi H, Lazarovits A, Butcher EC and Mäkelä PH: Homing potentials of circulating lymphocytes in humans depend on the site of activation: oral, but not parenteral, typhoid vaccination induces circulating antibody-secreting cells that all bear homing receptors directing them to the gut. J Immunol 158: 574-579, 1997.
63. Kantele A, Zivny J, Häkkinen M, Elson CO and Mestecky J: Differential Homing Commitments of Antigen-Specific T Cells After Oral or Parenteral Immunization in Humans. J Immunol 162: 5173-5177, 1999.
64. Matzinger P: Tolerance, danger, and the extended family. Ann Rev Immunol 12: 991-1045, 1994.
65. Fuchs EJ and Matzinger P: Is cancer dangerous to the immune system? Sem Immunol 8: 271-280, 1996.
66. Gallucci S, Lolkema M and Matzinger P: Natural adjuvants: endogenous activators of dendritic cells. Nat Med 5: 1249-1255, 1999.
67. Jacobs JJL, Lehé CL, Hasegawa H, Elliott GR and Das PK: Skin irritants and contact sensitizers induce Langerhans cell migration and maturation at irritant concentration. Exp Derm 15: 432-440, 2006.
68. Drexhage HA, Mullink H, de Groot J, Clarke J and Balfour BM: A study of cells present in peripheral lymph of pigs with special reference to a type of cell resembling the Langerhans cell. Cell Tissue Res 202: 407-430, 1979.
69. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, and Palucka K: Immunobiology of dendritic cells. Ann Rev Immunol 18: 767-811, 2000.
70. + T-helperand a T-killer cell. Nature 393: 474-478, 1998.
71. Everse LA, Bernsen MR, Dullens HFJ and Den Otter W: Priming of the antitumor response promotes efficacy of interleukin-2 therapy. Cancer Immunol Immunother 44: 221-229, 1997.
72. Everse LA, Renes IB, Jürgenliemk-Schulz IM, Rutgers DH, Bernsen MR, Dullens HFJ, Den Otter W and Battermann JJ: Local low-dose interleukin-2 induces systemic immunity when combined with radiotherapy of cancer. A pre-clinical study. Int J Cancer 72: 1003-1007, 1997.
73. Harris TJ, Hipkiss EL, Borzillary S, Wada S, Grosso JF, Yen HR, Getnet D, Bruno TC, Goldberg MV, Pardoll DM, DeWeese TL and Drake CG: Radiotherapy augments the immune response to prostate cancer in a time-dependent manner. Prost 68: 1319-1329, 2008.
74. Perez CA, Fu A, Onishko H, Hallahan DE and Geng L: Radiation induces an antitumour immune response to mouse melanoma. Int J Rad Biol 85: 1126-1136, 2009.
75. Chu Y, Wang LX, Yang G, Ross HJ, Urba W and J PR: Efficacy of GM-CSF-producing tumor vaccine after docetaxel chemotherapy in mice bearing established Lewis lung carcinoma. J Immunother 29: 367-380, 2006.
76. Wada S, Yoshimura K, Hipkiss EL, Harris TJ, Yen HR, Goldberg MV, Grosso JF, Getnet D, Demarzo AM, Netto GJ, Anders R, Pardoll DM and Drake CG: Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. Cancer Res 69: 4309-4318, 2009.
77. Formenti SC and Demaria S: Systemic effects of local radiotherapy. Lancet Oncol 10: 718-726, 2009.
78. Verhagen PCMS, Schröder FH, Collette L and Bangma CH: Does local treatment of the prostate in advanced and/or lymph node metastatic disease improve efficacy of androgen-deprivation therapy? A systematic review. Eur Urol 58: 261-269, 2010.
79. Nesslinger NJ, Sahota RA, Stone B, Johnson K, Chima N, King C, Rasmussen D, Bishop D, Rennie PS, Gleave M, Blood P, Pai H, Ludgate C and Nelson BH: Standard treatments induce antigen-specific immune responses in prostate cancer. Clin Cancer Res 13: 1493-1502, 2007.
80. Fujita T, Teh BS, Timme TL, Mai WY, Satoh T, Kusaka N, Naruishi K, Fattah EA, Aguilar-Cordova E, Butler EB and Thompson TC: Sustained long-term immune responses after in situ gene therapy combined with radiotherapy and hormonal therapy in prostate cancer patients. Int J Rad Oncol Biol Physiol 65: 84-90, 2006.
81. Aguilar LK, Teh B, Mai W, Caillouet J, Ayala G, Aguilar-Cordova E and Butler E: Five year follow up of a phase II study of cytotoxic immunotherapy combined with radiation in newly diagnosed prostate cancer. J Clin Oncol 24: (18S) 4635, 2006.
82. Spanos WC, Nowicki P, Lee DW, Hoover A, Hostager B, Gupta A, Anderson ME and Lee JH: Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer. Arch Otolaryngol Head Neck Surg 135: 1137-1146, 2009.
83. Jacobs JJL, Hordijk GJ, Jürgenliemk-Schulz IM, Terhaard CHJ, Koten JW, Battermann JJ and Den Otter W: Treatment of stage III-IV nasopharyngeal carcinomas by external beam irradiation and local low doses of IL-2. Cancer Immunol Immunother 54: 792-798, 2005.
84. Jourdier TM, Moste C, Bonnet MC, Delisle F, Tafani JP, Devauchelle P, Tartaglia J and Moingeon P: Local immunotherapy of spontaneous feline fibrosarcomas using recombinant poxviruses expressing interleukin 2 (IL2). Gene Ther 10: 2126-2132, 2003.
85. Weide B, Eigentler TK, Pflugfelder A, Leiter U, Meier F, Bauer J, Schmidt D, Radny P, Pföhler C and Garbe C: Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up. Cancer Immunol Immunother 60: 487-493., 2011.
86. Spoormakers TJ, Klein WR, Jacobs JJL, Van Den Ingh TS, Koten JW and Den Otter W: Comparison of the efficacy of local treatment of equine sarcoids with IL2 or cisplatin/IL2. Cancer Immunol Immunother 52: 179-184, 2003.
87. Kaasinen E, Rintala E, Hellström P, Viitanen J, Juusela H, Rajala P, Korhonen H and Liukkonen T: Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur Urol 42: 167-174, 2002.
88. Antonarakis ES and Carducci MA: Combining low-dose cyclophosphamide with GM-CSF-secreting prostate cancer immunotherapy enhances antitumor immune effects. Exp Op Invest Drugs 19: 311-314, 2010.
89. Miller AM and Pisa P: Tumor escape mechanisms in prostate cancer. Cancer Immunol Immunother 56: 81-87, 2007.
90. Wang R-F: Regulatory T-cells and innate immune regulation in tumor immunity. Springer Sem Immunol 28: 17-23, 2006.
91. Daniels GA, Sanchez-Perez L, Diaz RM, Kottke T, Thompson J, Lai M, Gough M, Karim M, Bushell A, Chong H, Melcher A, Harrington K and Vile RG: A simple method to cure established tumors by inflammatory killing of normal cells. Nat Biotech 22: 1129-1132, 2004.
92. + T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2. J Immunol 171: 5051-5063, 2003.
93. Ruffini PA, Morandi P, Cabioglu N, Altundag K and M. Cristofanilli: Manipulating the Chemokine-Chemokine Receptor Network to Treat Cancer. Cancer 109: 2392-2404, 2007.
94. Jackaman C, Lew AM, Zhan Y, Allan JE, Koloska B, Graham PT, Robinson BW and Nelson DJ: Deliberately provoking local inflammation drives tumors to become their own protective vaccine site. Int Immunol 20: 1467-1479, 2008.
95. Jacobs JJL, Sparendam D and Den Otter W: Local interleukin 2 therapy is most effective against cancer when injected intra-tumourally. Cancer Immunol Immunother 54: 647-654, 2005.
96. Kurth KH, Bouffioux C, Sylvester R, van der Meijden AP, Oosterlinck W and Brausi M: Treatment of superficial bladder tumors: achievements and needs. The EORTC Genitourinary Group. Eur Urol 37(Suppl 3): 1-9, 2000.
97. Malmström PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E, Solsona E, Di Stasi SM and Witjes JA: An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 56: 247-256, 2009.
98. Kresowik TP and Griffith TS: Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladder. Immunotherapy 1: 281-288, 2009.
99. Morales A: Evolution of intravesical immunotherapy for bladder cancer: mycobacterial cell wall preparation as a promising agent. Exp Op Invest Drugs 17: 1265, 2008.
100. Shelley MD, Mason MD and Kynaston H: Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses. Cancer Treatm Rev 36: 195-205, 2010.
101. Totterman TH, Loskog A and Essand M: The immunotherapy of prostate and bladder cancer. BJU international 96: 728-735, 2005.
102. Böhle A and Brandau S: Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol 170: 964-969, 2003.
103. Saint F, Kurth N, Maille P, Vordos D, Hoznek A, Soyeux P, Patard JJ, Abbou CC and Chopin DK: Urinary IL-2 assay for monitoring intravesical Bacillus Calmette-Guérin response of superficial bladder cancer during induction course and maintenance therapy. Int J Cancer 107: 434-440, 2003.
104. Tubaro A, Stoppacciaro A, Velotti F, Bossola PC, Cusumano G, Vicentini C, De Carli P, Ruco L, Santoni A and Cancrini A: Local immunotherapy of superficial bladder cancer by intravesical instillation of recombinant interleukin-2. Eur Urol 28: 297-303, 1995.
105. Ferlazzo G, Magno C, Iemmo R, Rizzo M, Lupo G, Semino C, Bruno S and Melioli G: Treatment of superficial bladder cancer with intravesical perfusion of rIL-2: a follow-up study. Anticanc Res 16: 979-980, 1996.
106. Den Otter W, Dobrowolski Z, Bugajski A, Papla B, Van Der Meijden APM, Koten JW, Boon TA, Siedlar M and Zembala M: Intravesical interleukin-2 in T1 papillary bladder carcinoma: regression of marker lesion in 8 of 10 patients. J Urol 159: 1183-1186, 1998.
107. Grasso M, Torelli F, Scannapieco G, Franzoso F and Lania C: Neoadiuvant treatment with intravesical interleukin-2 for recurrent superficial transitional bladder carcinoma Ta-T1/G1-2. J Immunother 24: 184-187, 2001.
108. Shaker MA and Younes HM: Interleukin-2: Evaluation of routes of administration and current delivery systems in cancer therapy. J Pharm Sci 98: 2268-2298, 2009.
109. Lichtor T, Glick RP, Awa G, Hardman J and Feldman LA: Advantages of intracerebral versus systemic administration of a DNA-based vaccine in treatment of an intracerebral tumor Gene Ther Mol Biol 12A: 1-6, 2008.
110. Chi K, Myers J, Chow K, Chan W, Tsang Y, Chao Y, Yen S and Lotze M: Phase II trial of systemic recombinant interleukin-2 in the treatment of refractory nasopharyngeal carcinoma. Oncology 60: 110-115, 2001.
111. Atallah E and Flaherty L: Treatment of metastatic malignant melanoma. Curr Treatm Opt Oncol 6: 185-193, 2005.
112. Atkins M, Lotze M, Dutcher J, Fisher R, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L and SA R: High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17: 2105-2116, 1999.
113. Radny P, Caroli UM, Bauer J, Paul T, Schlegel C, Eigentler TK, Weide B, Schwarz M and Garbe C: Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer 89: 1620-1626, 2003.
114. Smith FO, Downey SG, Klapper JA, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Restifo NP, Levy CL, White DE, Steinberg SM and Rosenberg SA: Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res 14: 5610-5618, 2008.
115. Weide B, Derhovanessian E, Pflugfelder A, Eigentler TK, Radny P, Zelba H, Pföhler C, Pawelec G and Garbe C: High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma. Cancer 116: 4139-4146, 2010.
116. Su Z, Vieweg JW, Dannull J and Dahm P: Vaccination of metastatic prostate cancer patients using mature dendritic cells transfected with mRNA encoding hTERT or an MHC class II targeted hTERT/LAMP fusion protein: Results from a phase I clinical trial. J Clin Oncol 22: (14S) 2507, 2004.
117. Valdagni R, Marrari A, Squarcina P, Villa S, Filipazzi P, Salvioni R, Rancati T, Asioli M, Parmiani G and Rivoltini L: Vaccination with survivin and PSMA-derived peptides for controlling biochemical recurrence in prostate cancer: A pilot study J Clin Oncol 27: (15S) e16042 2009.
118. Tanaka M, Uemura H, Uejima S, Fujimoto K, Hirao Y and Itoh K: Phase I/II study of individualized peptide vaccines for HLA-A2/A24-positive patients with hormone-refractory prostate cancer. J Clin Oncol 26: (15S) 5155, 2008.
119. McNeel DG, Dunphy EJ, Davies JG, Frye TP, Johnson LE, Staab MJ, Horvath DL, Straus J, Alberti D, Marnocha R, Liu G, Eickhoff JC and Wilding G: Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol 27: 4047-4054, 2009.
120. Perambakam S, Xie H, Edassery S and Peace DJ: Long-Term Follow-Up of HLA-A2+ Patients with High-Risk, Hormone-Sensitive Prostate Cancer Vaccinated with the Prostate Specific Antigen Peptide Homologue (PSA146-154). Clin Dev Immunol 2010: 473453, 2010.
121. Perez SA, Kallinteris NL, Bisias S, Tzonis PK, Georgakopoulou K, Varla-Leftherioti M, Papamichail M, Thanos A, von Hofe E and Baxevanis CN: Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer. Clin Cancer Res 16: 3495-3506, 2010.
122. Uemura H, Fujimoto K, Mine T, Uejima S, de Velasco MA, Hirao Y, Komatsu N, Yamada A and Itoh K: Immunological evaluation of personalized peptide vaccination monotherapy in patients with castration-resistant prostate cancer. Cancer Sci 101: 601-608, 2010.
123. Slovin SF, Ragupathi G, Musselli C, Olkiewicz K, Verbel D, Kuduk SD, Schwarz JB, Sames D, Danishefsky S, Livingston PO and Scher HI: Fully Synthetic Carbohydrate-Based Vaccines in Biochemically Relapsed Prostate Cancer: Clinical Trial Results With α-N-Acetylgalactosamine-O-Serine/Threonine Conjugate Vaccine. J Clin Oncol 23: 4292-4298, 2003.
124. Aena DA, Joudi F, Williams RD, Eastman J, Flanders E, Zehr P, Griffith K and Lubaroff D: Adenovirus-PSA vaccination in recurrent and castration-resistant prostate cancer: Phase II trial interim results. J Clin Oncol 29: (15S) e15070, 2010
125. Kaufman HL, Wang W, Manola J, DiPaola RS, Y.-J. Ko, Sweeney C, Whiteside TL, Schlom J, Wilding G and Weiner LM: Phase II Randomized Study of Vaccine Treatment of Advanced Prostate Cancer (E7897): A Trial of the Eastern Cooperative Oncology Group. J Clin Oncol 22: 2122-2132, 2004.
126. Pandha HS, Michael A, Quatan N, Wushishi F, Russell N, Whelan J and Whelan M: The effect of whole cell allogeneic vaccination on the progression of hormone-relapsed prostate cancer. J Clin Oncol 22: (14S) 4735, 2004.
127. Dalgleish AG, Quatan N, Michael A, Wushishi F and Pandha H: Increased time to progression and sustained PSA velocity responses in a phase II trial in advanced metastatic prostate cancer following treatment with ONY-P1, an allogeneic whole cell vaccine. J Clin Oncol 23: (16S) 4726, 2005.
128. Beinart G, Rini BI, Weinberg V and Small EJ: Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer. Clin Prost Cancer 4: 55-60, 2005.
129. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA and Hershberg RM: Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone-refractory prostate cancer. J Clin Oncol 24: 3089-3094, 2006.
130. Dueland S, Mu L-J, Kvalheim G, Hauser M, Waehre H, Aamdal S and Gaudernack G: Dendritic cells transfected with allo-tumor mRNA as cancer vaccine in treatment of hormone resistant prostate cancer patients. J Clin Oncol 23: (16S) 2541, 2005.
131. Higano CS, Corman JM, Smith DC, Centeno AS, Steidle CP, Gittleman M, Simons JW, Sacks N, Aimi J and Small EJ: Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 113: 975-984, 2008.
132. Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I and Allison JP: A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 13: 1810-1816, 2007.
133. Simons JW, Carducci MA, Mikhak B, Lim M, Biedrzycki B, Borellini F, Clift SM, Hege KM, Ando DG, Piantadosi S, Mulligan R and Nelson WG: Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer. Clin Cancer Res 12: 3394-3401, 2006.
134. Arlen PM, Gulley JL, Parker C, Skarupa L, Pazdur M, Panicali D, Beetham P, Tsang K Y, Grosenbach DW, Feldman J, Steinberg SM, Jones E, Chen C, Marte J, Schlom J and Dahut W: A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 12: 1260-1269, 2006.
135. Pantuck AJ, van Ophoven A, Gitlitz BJ, Tso CL, Acres B, Squiban P, Ross ME, Belldegrun AS and Figlin RA: Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer. J Immunother 27: 240-253, 2004.
136. Dreicer R, Stadler WM, Ahmann FR, Whiteside T, Bizouarne N, Acres B, Limacher JM, Squiban P and Pantuck A: MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure. Invest New Drugs 27: 379-386, 2009.
137. Gansbacher B, Brill T, Eisele B, Kuebler H, Randenborgh Hv, Paul R, Hartung R, Fend F, Pohla H and Schendel D: Cancer gene therapy with a retrovirally transduced IL2-IFN{gamma}-secreting allogeneic tumorvaccine in patients with progressive hormone refractory prostate cancer-A phase I/II trial. J Clin Oncol 25: (18S) 5127, 2007.
138. Brill TH, Kübler HR, Pohla H, Buchner A, Fend F, Schuster T, van Randenborgh H, Paul R, Kummer T, Plank C, Eisele B, Breul J, Hartung R, Schendel DJ and Gansbacher B: Therapeutic vaccination with an interleukin-2-interferon-gamma-secreting allogeneic tumor vaccine in patients with progressive castration-resistant prostate cancer: a phase I/II trial. Human Gene Ther 20: 1641-1651, 2009.
139. Madan RA, Mohebtash M, Arlen PM, Vergati M, Steinberg SM, Tsang KY, Dahut WL, Schlom J and Gulley JL: Overall survival (OS) analysis of a phase l trial of a vector-based vaccine (PSA-TRICOM) and ipilimumab (Ipi) in the treatment of metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 28: (15S) 2550, 2010.
140. Gerritsen W, Van Den Eertwegh AJ, De Gruijl T, Giaccone G, Scheper RJ, Lowy I, Levy E, Hege K and Sacks N: A dose-escalation trial of GM-CSF-gene transducted allogeneic prostate cancer cellular immunotherapy in combination with a fully human anti-CTLA4 antibody (MDX-010, ipilimumab) in patients with metastatic hormone-refractory prostate cancer (mHRPC). J Clin Oncol 24: S2500, 2006.
141. Fong L, Kwek SS, O'Brien S, Kavanagh B, McNeel DG, Weinberg V, Lin AM, Rosenberg J, Ryan CJ, Rini BI and Small EJ: Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res 69: 609-615, 2009.
142. Mohebtash M, Madan RA, Arlen PM, Rauckhorst M, Tsang KY, Cereda V, Vergati M, Poole DJ, Dahut WL, Schlom J, and Gulley JL: Phase I trial of targeted therapy with PSA-TRICOM vaccine (V) and ipilimumab (ipi) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2009: (15S) 5144, 2009.
143. Arlen PM, Skarupa L, Pazdur M, Seetharam M, Tsang KY, Grosenbach DW, Feldman J, Poole DJ, Litzinger M, Steinberg SM, Jones E, Chen C, Marte J, Parnes H, Wright J, Dahut W, Schlom J and Gulley JL: Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urol 178: 1515-1520, 2007.
144. DiPaola RS, Plante M, Kaufman H, Petrylak DP, Israeli R, Lattime E, Manson K and Schuetz T: A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J Transl Med 4: 1-5, 2006.
145. Petrylak DP, Tangen CM, Hussain MH, Lara PNJ, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D and Crawford ED: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. New Engl J Med 351: 1513-1520, 2004.